ANIMATION

Gleevec (imatinib) MOA

Share this animation:

Kit is a receptor tyrosine kinase that activates of a number of pathways that direct cell proliferation, survival, and apoptosis. Mutations in Kit that result in constitutive oligomerization in the absence of ligand can drive continuous oncogenic signaling. The majority of gastrointestinal stromal tumor (GIST) cells have been found to present with overactive Kit signaling. Gleevec, or Glivec (imatinib mesylate) competitively binds to the ATP binding pocket of both active and inactive Kit, preventing downstream signaling. Kit inhibition by imatinib may induce both apoptosis and quiescence in KIT+ GIST cells.

Share It:
Contact XVIVO

Client


Novartis

DARPA was very pleased with the Trauma Pod of the Future video. It was instrumental in presenting this futuristic and complex research program and provided an insight to the audience and reviewers that they would not have otherwise achieved. The quality of the work is exceptional and the video has been shown hundreds of times with great success; it is one of the most popular videos that I have used in my presentations.

Richard Satava, MD, Program Manager, Advanced Biomedical Technologies Program, DARPA
Share this animation: